INMB Share Price | INmune Bio, Inc. Stock Analysis & Recommendation

Q: How big is INmune Bio, Inc.?

Market Cap: As of Jun 18, INmune Bio, Inc. has a market capitalization of 159.46 million, classified as a Micro Cap.Recent Quarterly Performance: For the latest four quarters, the company reported net sales of 0.05 million and a net profit of -40.80 million.Balance Sheet Snapshot: As of Dec 24, the company's shareholder's funds amounted to 32.10 million, while total assets were reported at 39.56 million.

Q: What does INmune Bio, Inc. do?

Overview: INmune Bio, Inc. is a clinical-stage pharmaceutical immunotherapy company focused on developing strategies for oncology by harnessing the innate immune system to treat cancer, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.Financial Snapshot: Most recent Net Sales: 0 Million (Quarterly Results - Mar 2025) Most recent Net Profit: -10 Million (Quarterly Results - Mar 2025) Market cap: USD 159.46 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -0.65 Return on Equity: -137.49% Price to Book: 5.37Contact Details: Address: 1200 Prospect St Ste 525, LA JOLLA CA: 92037-3608 Tel: 1 858 9643720 Website: http://www.inmunebio.com/

Q: Is INmune Bio, Inc. technically bullish or bearish?

As of 10 July 2025, the technical trend for INmune Bio, Inc. has changed from mildly bearish to bearish. The current technical stance is bearish with a strong indication from multiple indicators. The MACD is bearish on both weekly and monthly time frames, and the Bollinger Bands also reflect a bearish trend in both periods. Moving averages are bearish on the daily chart, and Dow Theory confirms a bearish stance on both weekly and monthly levels. The RSI shows a bullish signal on the weekly but no signal on the monthly, indicating mixed momentum. In terms of performance, the stock has significantly underperformed compared to the S&P 500, with a year-to-date return of -57.82% versus the S&P 500's 12.22%, and a one-year return of -62.04% compared to 17.14% for the index. Overall, the bearish indicators suggest a challenging outlook for the stock.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

39.83 k

Shareholding (Sep 2025)

FII

8.61%

Held by 33 FIIs

DII

81.08%

Held by 11 DIIs

Promoter

0.00%

How big is INmune Bio, Inc.?

22-Jun-2025

As of Jun 18, INmune Bio, Inc. has a market capitalization of 159.46 million and reported net sales of 0.05 million with a net profit of -40.80 million over the last four quarters. Shareholder's funds were 32.10 million, and total assets were 39.56 million as of Dec 24.

View full answer

What does INmune Bio, Inc. do?

22-Jun-2025

INmune Bio, Inc. is a clinical-stage pharmaceutical company focused on developing immunotherapy treatments for cancer. It has a market cap of approximately $159.46 million, with recent net sales of $0 million and a net loss of $10 million.

View full answer

Is INmune Bio, Inc. technically bullish or bearish?

20-Sep-2025

As of July 10, 2025, INmune Bio, Inc. is in a bearish trend with multiple indicators confirming this stance, including bearish MACD and moving averages, and has significantly underperformed the S&P 500 with a year-to-date return of -57.82%.

View full answer

Compare INmune Bio, Inc. with Similar Stocks

BioVie, Inc.Design Therapeutics, Inc.Trevi Therapeutics, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 36 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.07

Return on Equity

-133.87%

Price to Book

1.41

Revenue and Profits:

Net Sales:

(Quarterly Results - Sep 2025)

Net Profit:

-6 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-31.07%

6 Months

-37.44%

1 Year

-85.3%

2 Years

-90.0%

3 Years

-81.4%

4 Years

-86.65%

5 Years

-90.08%

INmune Bio, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

0.98%

EBIT Growth (5y)

-201.39%

EBIT to Interest (avg)

-25.68

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.65

Sales to Capital Employed (avg)

0.00

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

38.84%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

1.41

EV to EBIT

-0.25

EV to EBITDA

-0.25

EV to Capital Employed

-4.54

EV to Sales

8.61

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-133.87%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

Bearish

RSI

No Signal

Bullish

Bollinger Bands

Mildly Bearish

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Dow Theory

Mildly Bearish

OBV

No Trend

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 12 Schemes (10.31%)

Foreign Institutions

Held by 33 Foreign Institutions (8.61%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Sep 2025 is 0.00% vs -100.00% in Jun 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Sep 2025 is 73.47% vs -152.58% in Jun 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Jun'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-7.40",
          "val2": "-8.10",
          "chgp": "8.64%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.60",
          "val2": "-16.50",
          "chgp": "103.64%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-6.50",
          "val2": "-24.50",
          "chgp": "73.47%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -100.00% vs -50.00% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -40.33% vs -9.89% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.20",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-42.60",
          "val2": "-29.70",
          "chgp": "-43.43%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-42.10",
          "val2": "-30.00",
          "chgp": "-40.33%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-3,045,357.10%",
          "val2": "-191,877.40%",
          "chgp": "-2,85,347.97%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ

Sep'25

Jun'25

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-7.40

-8.10

8.64%

Interest

0.00

Exceptional Items

0.60

-16.50

103.64%

Consolidate Net Profit

-6.50

-24.50

73.47%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Sep 2025 is 0.00% vs -100.00% in Jun 2025

Consolidated Net Profit

QoQ Growth in quarter ended Sep 2025 is 73.47% vs -152.58% in Jun 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.00

0.20

-100.00%

Operating Profit (PBDIT) excl Other Income

-42.60

-29.70

-43.43%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-42.10

-30.00

-40.33%

Operating Profit Margin (Excl OI)

-3,045,357.10%

-191,877.40%

-2,85,347.97%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is -100.00% vs -50.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -40.33% vs -9.89% in Dec 2023

All Annual Results

Company CV

About INmune Bio, Inc.

INmune Bio, Inc.

Pharmaceuticals & Biotechnology

Inmune Bio Inc. is a clinical-stage pharmaceutical immunotherapy company. The Company is focused on developing strategies for oncology that focus on re-engineering and harnessing the innate immune system to treat the patient’s cancer. The Company’s product candidates (INMB) target cells of the innate immune system that include natural killer cells (NK cells) and myeloid derived suppressor cells, (MDSC cells). The NK cell of the innate immune system has two primary functions, such as to kill virally infected cells and to kill cancer cells. Its INB03 is a protein biologic that has beneficial effects in patients with cancer. Its initial focus is on its ability to inhibit proliferation and function of myeloid-derived suppressor cells (MDSC).

Company Coordinates

Company Details

1200 Prospect St Ste 525 , LA JOLLA CA : 92037-3608

Tel: 1 858 9643720

http://www.inmunebio.com/

Registrar Details